Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Public ClinicalTrials.gov record NCT01870609. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Study identification
- NCT ID
- NCT01870609
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Verastem, Inc.
- Industry
- Enrollment
- 344 participants
Conditions and interventions
Conditions
Interventions
- defactinib (VS-6063) Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2013
- Primary completion
- Dec 31, 2015
- Completion
- Dec 31, 2015
- Last update posted
- Jan 29, 2017
2013 – 2016
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco Medical Center | San Francisco | California | — | — |
| Cleveland Clinic Florida | Weston | Florida | 33331 | — |
| University of Chicago Medical Center | Chicago | Illinois | — | — |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | — | — |
| Mayo Clinic | Rochester | Minnesota | — | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Jacobi Medical Center | The Bronx | New York | 10461 | — |
| Cleveland Clinic | Cleveland | Ohio | — | — |
| Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | — | — |
| UT Southwestern | Dallas | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01870609, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01870609 live on ClinicalTrials.gov.